Regulatory challenges for the next wave of cancer therapies
Room: KERNHEM 1-2
Time: 09:00 to 11:00
Chair: Sjaak Bot (Janssen)
Organizing FIGON partner: Regulatory Science Network Netherlands (RSNN)
A wave of innovative oncology treatments is progressing from bench to clinic. This includes treatment strategies such as chimeric T cell receptors (CAR-T) and other approaches that are categorized as Advanced Therapy Medicinal Products by the EMA. These products have the potential to transform the future of oncological treatment, but require innovative approaches concerning the risk-benefit assessment and subsequent market access. In this session we will discuss questions such as: Is the current regulatory landscape ready to facilitate registration of these innovative therapies to patients at the earliest appropriate time? Can we learn from the hurdles and barriers in the current ATMP regulation to prepare ourselves for new cancer therapies such as CAR-T?
09:00 - 09:10 Introduction
Invited lectures:
09:10 - 09:35
Regulatory considerations for ATMP based cancer therapies
Dr. Marcel Hoefnagel – Medicines Evaluation Board (CBG-MEB)
09:35 - 10:00
Planning for successful and efficient ATMP development
Dr. Harm Hermsen – Xendo
10:00 - 10:25
Access to innovative cancer therapies: the patient view
Dr. Pauline Evers – nfk
Selected abstracts:
10:25 - 10:40
Challenges in Commercial Advanced Therapy Development in Europe
Renske ten Ham - Utrecht University
10:40 - 11:00 Panel discussion
Indicated speaker time includes 5 minutes for discussion
Almost done…
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly